Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression

PLoS Pathogens

Volumn 8, Issue 1, 2012, Pages

  Osorio, E Yaneth ^a,b,d   Zhao, Weiguo ^a,b   Espitia, Claudia ^a,b   Saldarriaga, Omar ^a,b,d   Hawel, Leo ^c   Byus, Craig V ^c   Travi, Bruno L ^a,b,d   Melby, Peter C ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CYTOKINE; INTERLEUKIN 4; MESSENGER RNA; NITRIC OXIDE; POLYAMINE; STAT6 PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FIBROBLAST; HAMSTER; LEISHMANIA DONOVANI; MACROPHAGE ACTIVATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE; PATHOGENESIS; PERITONEUM; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARGINASE; ARGININE; BASE SEQUENCE; CRICETINAE; CYTOKINES; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGE ACTIVATION; MACROPHAGES; MESOCRICETUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; POLYAMINES; SEQUENCE ANALYSIS, DNA; SPLEEN; STAT6 TRANSCRIPTION FACTOR; TIME FACTORS;

CRICETINAE;

EID: 84857484458     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002417     Document Type: Article

References (106)

1. Barbosa Junior AA, Andrade ZA, Reed SG, (1987) The pathology of experimental visceral leishmaniasis in resistant and susceptible lines of inbred mice. Braz J Med Biol Res 20: 63-72.
2. Murray HW, Nathan CF, (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-746.
3. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, et al. (1989) Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 143: 4244-4249.
4. Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW, (1988) Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol 140: 3971-3977.
5. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
6. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, et al. (2003) Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis 188: 458-464.
7. Wilson ME, Recker TJ, Rodriguez NE, Young BM, Burnell KK, et al. (2002) The TGF-beta response to Leishmania chagasi in the absence of IL-12. Eur J Immunol 32: 3556-3565.
8. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
9. Kaye PM, Curry AJ, Blackwell JM, (1991) Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146: 2763-2770.
10. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D, (1993) Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis 168: 986-993.
11. Hailu A, van der Poll T, Berhe N, Kager PA, (2004) Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71: 561-567.
12. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, et al. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324-329.
13. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S, (1998) Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 177: 815-818.
14. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, et al. (1993) In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]. J Clin Invest 91: 1644-1648.
15. Bogdan C, Nathan C, (1993) Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci 685: 713-739.
16. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
17. Wilson ME, Jeronimo SM, Pearson RD, (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147-160.
18. Babaloo Z, Kaye PM, Eslami MB, (2001) Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg 95: 85-88.
19. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
20. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW, (1997) Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 56: 522-525.
21. Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, et al. (1990) Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol 57: 242-249.
22. Ansari NA, Saluja S, Salotra P, (2006) Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 119: 339-345.
23. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182-191.
24. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, et al. (2006) Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69: 353-358.
25. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, et al. (2005) Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
26. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, et al. (1994) Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956.
27. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, et al. (2011) IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 204: 1134-1137.
28. Olivier M, Gregory DJ, Forget G, (2005) Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 18: 293-305.
29. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, et al. (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375: 408-411.
30. MacMicking J, Xie QW, Nathan C, (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350.
31. Green SJ, Meltzer MS, Hibbs JB Jr, Nacy CA, (1990) Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 144: 278-283.
32. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S, (1990) Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797.
33. Liew FY, Li Y, Moss D, Parkinson C, Rogers MV, et al. (1991) Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 21: 3009-3014.
34. Stenger S, Thuring H, Rollinghoff M, Bogdan C, (1994) Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 180: 783-793.
35. Stenger S, Donhauser N, Thuring H, Rollinghoff M, Bogdan C, (1996) Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med 183: 1501-1514.
36. Gordon S, Martinez FO, (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
37. Stein M, Keshav S, Harris N, Gordon S, (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292.
38. Iniesta V, Gomez-Nieto LC, Corraliza I, (2001) The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J Exp Med 193: 777-784.
39. Stempin C, Giordanengo L, Gea S, Cerban F, (2002) Alternative activation and increase of Trypanosoma cruzi survival in murine macrophages stimulated by cruzipain, a parasite antigen. J Leukoc Biol 72: 727-734.
40. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, et al. (2006) The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116: 2044-2055.
41. Raes G, Beschin A, Ghassabeh GH, De Baetselier P, (2007) Alternatively activated macrophages in protozoan infections. Curr Opin Immunol 19: 454-459.
42. Iniesta V, Gomez-Nieto LC, Molano I, Mohedano A, Carcelen J, et al. (2002) Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 24: 113-118.
43. Iniesta V, Carcelen J, Molano I, Peixoto PM, Redondo E, et al. (2005) Arginase I induction during Leishmania major infection mediates the development of disease. Infect Immun 73: 6085-6090.
44. Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, et al. (2005) Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J 19: 1000-1002.
45. Colotti G, Ilari A, (2011) Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids 40: 269-285.
46. Iniesta V, Carlos Gomez-Nieto L, Molano I, Mohedano A, Carcelen J, et al. (2002) Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 24: 113-118.
47. Gifawesen C, Farrell JP, (1989) Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect Immun 57: 3091-3096.
48. Melby PC, Chandrasekar B, Zhao W, Coe JE, (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like response. J Immunol 166: 1912-1920.
49. Perez LE, Chandrasekar B, Saldarriaga OA, Zhao W, Arteaga LT, et al. (2006) Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol 176: 5519-5528.
50. Rahimi F, Hsu K, Endoh Y, Geczy CL, (2005) FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8. FEBS J 272: 2811-2827.
51. Sacks DL, Melby PC, (2001) Animal models for the analysis of immune responses to leishmaniasis. Curr Protoc Immunol Chapter 19 (Unit 19): 12.
52. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, et al. (2000) Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 110: 195-206.
53. Osorio Y, Travi BL, Renslo AR, Peniche AG, Melby PC, (2011) Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. PLoS Negl Trop Dis 5: e962.
54. Herzfeld A, Raper SM, (1976) The heterogeneity of arginases in rat tissues. Biochem J 153: 469-478.
55. Corraliza IM, Campo ML, Soler G, Modolell M, (1994) Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 174: 231-235.
56. Gilbert RS, Gonzalez GG, Hawel L 3rd, Byus CV, (1991) An ion-exchange chromatography procedure for the isolation and concentration of basic amino acids and polyamines from complex biological samples prior to high-performance liquid chromatography. Anal Biochem 199: 86-92.
57. Hawel L 3rd, Tjandrawinata RR, Fukumoto GH, Byus CV, (1994) Biosynthesis and selective export of 1,5-diaminopentane (cadaverine) in mycoplasma-free cultured mammalian cells. J Biol Chem 269: 7412-7418.
58. Hawel L 3rd, Byus CV, (2002) A streamlined method for the isolation and quantitation of nanomole levels of exported polyamines in cell culture media. Anal Biochem 311: 127-132.
59. Espitia CM, Zhao W, Saldarriaga OA, Osorio Y, Harrison LM, et al. (2010) Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis. BMC Immunol 11: 31.
60. Melby PC, Tryon VV, Chandrasekar B, Freeman GL, (1998) Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 66: 2135-2142.
61. Rothman P, Li SC, Gorham B, Glimcher L, Alt F, et al. (1991) Identification of a conserved lipopolysaccharide-plus-interleukin-4-responsive element located at the promoter of germ line epsilon transcripts. Mol Cell Biol 11: 5551-5561.
62. Salimuddin, Nagasaki A, Gotoh T, Isobe H, Mori M, (1999) Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am J Physiol 277: E110-117.
63. Muleme HM, Reguera RM, Berard A, Azinwi R, Jia P, et al. (2009) Infection with arginase-deficient Leishmania major reveals a parasite number-dependent and cytokine-independent regulation of host cellular arginase activity and disease pathogenesis. J Immunol 183: 8068-8076.
64. Landfear SM, (2011) Nutrient transport and pathogenesis in selected parasitic protozoa. Eukaryot Cell 10: 483-493.
65. Ramya TN, Surolia N, Surolia A, (2006) Polyamine synthesis and salvage pathways in the malaria parasite Plasmodium falciparum. Biochem Biophys Res Commun 348: 579-584.
66. Seabra SH, DaMatta RA, de Mello FG, de Souza W, (2004) Endogenous polyamine levels in macrophages is sufficient to support growth of Toxoplasma gondii. J Parasitol 90: 455-460.
67. Morris SM Jr, (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 157: 922-930.
68. Biswas A, Bhattacharya A, Kar S, Das PK, (2011) Expression of IL-10-triggered STAT3-dependent IL-4Ralpha is required for induction of arginase 1 in visceral leishmaniasis. Eur J Immunol 41: 992-1003.
69. Riley E, Roberts SC, Ullman B, (2011) Inhibition profile of Leishmania mexicana arginase reveals differences with human arginase I. Int J Parasitol 41: 545-552.
70. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, et al. (2004) Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol 172: 7565-7573.
71. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, et al. (2001) Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol 166: 2173-2177.
72. Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, Duschl A, (2006) Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 17: 173-188.
73. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL, (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 5152-5158.
74. Stamm LM, Raisanen-Sokolowski A, Okano M, Russell ME, David JR, et al. (1998) Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol 161: 6180-6188.
75. Dent AL, Doherty TM, Paul WE, Sher A, Staudt LM, (1999) BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major. J Immunol 163: 2098-2103.
76. Nabeshima Y, Hiragun T, Morita E, Mihara S, Kameyoshi Y, et al. (2005) IL-4 modulates the histamine content of mast cells in a mast cell/fibroblast co-culture through a Stat6 signaling pathway in fibroblasts. FEBS Lett 579: 6653-6658.
77. Mora AL, Torres-Gonzalez E, Rojas M, Corredor C, Ritzenthaler J, et al. (2006) Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol 35: 466-473.
78. Yu B, Koga T, Urabe K, Moroi Y, Maeda S, et al. (2002) Differential regulation of thymus- and activation-regulated chemokine induced by IL-4, IL-13, TNF-alpha and IFN-gamma in human keratinocyte and fibroblast. J Dermatol Sci 30: 29-36.
79. Bogdan C, Donhauser N, Doring R, Rollinghoff M, Diefenbach A, et al. (2000) Fibroblasts as host cells in latent leishmaniosis. J Exp Med 191: 2121-2130.
80. Hespanhol RC, de Nazare CSM, Meuser MB, de Nazareth SLMM, Corte-Real S, (2005) The expression of mannose receptors in skin fibroblast and their involvement in Leishmania (L.) amazonensis invasion. J Histochem Cytochem 53: 35-44.
81. Kaye P, Scott P, (2011) Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 9: 604-615.
82. Caceres-Dittmar G, Tapia FJ, Sanchez MA, Yamamura M, Uyemura K, et al. (1993) Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol 91: 500-505.
83. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, et al. (1994) Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 62: 837-842.
84. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, et al. (1993) Cytokine patterns in the pathogenesis of human leishmaniasis [see comments]. J Clin Invest 91: 1390-1395.
85. Albina JE, Mahoney EJ, Daley JM, Wesche DE, Morris SM Jr, et al. (2005) Macrophage arginase regulation by CCAAT/enhancer-binding protein beta. Shock 23: 168-172.
86. Gray MJ, Poljakovic M, Kepka-Lenhart D, Morris SM Jr, (2005) Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 353: 98-106.
87. Valineva T, Yang J, Palovuori R, Silvennoinen O, (2005) The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. J Biol Chem 280: 14989-14996.
88. Robb BW, Hershko DD, Paxton JH, Luo GJ, Hasselgren PO, (2002) Interleukin-10 activates the transcription factor C/EBP and the interleukin-6 gene promoter in human intestinal epithelial cells. Surgery 132: 226-231.
89. Tanaka N, Hoshino Y, Gold J, Hoshino S, Martiniuk F, et al. (2005) Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol 33: 406-411.
90. Schreiber T, Ehlers S, Heitmann L, Rausch A, Mages J, et al. (2009) Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 183: 1301-1312.
91. Qualls JE, Neale G, Smith AM, Koo MS, DeFreitas AA, et al. (2010) Arginine usage in mycobacteria-infected macrophages depends on autocrine-paracrine cytokine signaling. Sci Signal 3: ra62.
92. Morris SM Jr, Kepka-Lenhart D, Chen LC, (1998) Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 275: E740-747.
93. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, et al. (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939.
94. Vouldoukis I, Becherel PA, Riveros-Moreno V, Arock M, da Silva O, et al. (1997) Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 27: 860-865.
95. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scotton C, et al. (2005) Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol 174 (6561; author reply): 6561-6562.
96. Babu S, Kumaraswami V, Nutman TB, (2009) Alternatively activated and immunoregulatory monocytes in human filarial infections. J Infect Dis 199: 1827-1837.
97. Ochoa JB, Bernard AC, O'Brien WE, Griffen MM, Maley ME, et al. (2001) Arginase I expression and activity in human mononuclear cells after injury. Ann Surg 233: 393-399.
98. Rodriguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
99. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, et al. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64: 5839-5849.
100. Noel W, Raes G, Hassanzadeh Ghassabeh G, De Baetselier P, Beschin A, (2004) Alternatively activated macrophages during parasite infections. Trends Parasitol 20: 126-133.
101. Stempin CC, Dulgerian LR, Garrido VV, Cerban FM, (2010) Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals. J Biomed Biotechnol.
102. Rogers M, Kropf P, Choi BS, Dillon R, Podinovskaia M, et al. (2009) Proteophosophoglycans regurgitated by Leishmania-infected sand flies target the L-arginine metabolism of host macrophages to promote parasite survival. PLoS Pathog 5: e1000555.
103. Ahn HJ, Kim JY, Ryu KJ, Nam HW, (2009) STAT6 activation by Toxoplasma gondii infection induces the expression of Th2 C-C chemokine ligands and B clade serine protease inhibitors in macrophage. Parasitol Res 105: 1445-1453.
104. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, et al. (2008) Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 9: 1399-1406.
105. Donnelly S, Stack CM, O'Neill SM, Sayed AA, Williams DL, et al. (2008) Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. Faseb J 22: 4022-4032.
106. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, et al. (1999) Alternative versus classical activation of macrophages. Pathobiology 67: 222-226.